{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:43:35Z","timestamp":1773157415050,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T00:00:00Z","timestamp":1335916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Carboplatin is a platinum analogue, widely used in the treatment of numerous cancer types including lung, genitourinary and ovarian cancers. It is also used in the adjuvant treatment of human epidermal growth factor receptor 2 positive breast cancer, where a non\u2010anthracycline regimen is preferred. It is considered generally to be less toxic though potentially less efficacious than cisplatin, another platinum compound. Cisplatin is well recognized as causing hyponatremia, through the mechanism of renal salt wasting. Conversely, carboplatin has only rarely been associated with hyponatremia. We report here a case of severe hyponatremia occurring 6\u2003days after adjuvant treatment with a carboplatin\u2010containing chemotherapy regimen for early stage breast cancer. The mechanism of hyponatremia was consistent with the syndrome of inappropriate anti\u2010diuretic hormone secretion based on biochemical and clinical findings, and response to fluid restriction. With no previously reported cases of docetaxel\u2010associated or trastuzumab\u2010associated hyponatremia, the causative agent was considered to be carboplatin. Additionally there was no recurrence of hyponatremia on recommencement of docetaxel and trastuzumab therapy. Hyponatremia secondary to carboplatin has been rarely reported in the literature, with only three previously reported cases. Although it is rare, oncologists should be aware of the potential for carboplatin to cause hyponatremia and the need to monitor electrolytes throughout therapy.<\/jats:p>","DOI":"10.1111\/j.1743-7563.2012.01526.x","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T02:22:06Z","timestamp":1336011726000},"source":"Crossref","is-referenced-by-count":7,"title":["Syndrome of inappropriate anti\u2010diuretic hormone secretion secondary to carboplatin after docetaxel\u2010carboplatin\u2010trastuzumab combination for early stage HER\u20102 positive breast cancer"],"prefix":"10.1111","volume":"8","author":[{"given":"Natalie","family":"TURNER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"STEWART","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"BARNETT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"WHITE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,2]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.153"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10990"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.8.1245"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.109"},{"key":"e_1_2_4_7_2","unstructured":"SlamonD EiermannW RobertNet\u2003al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at 29th Annual San Antonio Breast Cancer Symposium; 14\u201317 December2006; San Antonio TX. Abstract 52."},{"key":"e_1_2_4_8_2","first-page":"305","article-title":"Sodium\u2010wasting nephropathy caused by cisplatin in esophageal cancer","volume":"7","author":"Abdelghani L","year":"2008","journal-title":"J Support Oncol"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0309-9"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000209292"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.59.6.643"},{"key":"e_1_2_4_12_2","first-page":"729","article-title":"Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following carboplatin\u2010paclitaxel administration in a patient with lung cancer","volume":"66","author":"Fujioka S","year":"2011","journal-title":"Pharmazie"},{"key":"e_1_2_4_13_2","first-page":"531","article-title":"Syndrome of inappropriate secretion of anti\u2010diuretic hormone following carboplatin\u2010paclitaxel administration in a patient with recurrent ovarian cancer","volume":"26","author":"Yokoyama Y","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940315)73:6<1761::AID-CNCR2820730635>3.0.CO;2-#"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199808)31:2<129::AID-MPO21>3.0.CO;2-H"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1743-7563.2012.01526.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1743-7563.2012.01526.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:52:50Z","timestamp":1697374370000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1743-7563.2012.01526.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,2]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1743-7563.2012.01526.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-7563.2012.01526.x","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,2]]}}}